Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT-Reference-Cited by-同舟云学术

Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT

Published:2024-07 Issue: Volume: Page:
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Giebel Sebastian,Labopin Myriam,Peric Zinaida,Passweg Jakob,Blaise Didier^ORCID,Salmenniemi Urpu,Beauvais David^ORCID,Reményi Péter,Chevallier Patrice,Mielke Stephan,Gedde-Dahl Tobias^ORCID,Cornelissen Jan J.,Balsat Marie,Bug Gesine^ORCID,Bazarbachi Ali,Brissot Eolia,Nagler Arnon,Ciceri Fabio^ORCID,Mohty Mohamad

Publisher

Elsevier BV

Reference34 articles.

1. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group;Burmeister;Blood,2008

2. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial;Moorman;Blood,2007

3. Third International Workshop on chromosomes in leukemia: chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia;Bloomfield;Cancer Res,1983

4. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate;Thomas;Blood,2004

5. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study;de Labarthe;Blood,2007